• VistaGen completed last patient last visit in randomized, double-blind, placebo-controlled portion of PALISADE-4 Phase 3 study of fasedienol nasal spray for acute treatment of social anxiety disorder.
• Topline results have not been presented yet; release expected this quarter.
• Trial is designed to assess whether a single dose can reduce anxiety symptoms during a simulated public speaking challenge, with safety and tolerability also evaluated.
• Company refined primary efficacy analysis to account for participants’ distress level immediately before dosing; FDA indicated it had no comments on the change.
• Open-label extension remains ongoing, allowing continued use in daily life for up to 12 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260508181101) on May 08, 2026, and is solely responsible for the information contained therein.